• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tryp Therapeutics Inc (OP: TRYPF )

    N/A UNCHANGED
    Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Tryp Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder?
    Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding... 
    Via Benzinga
    PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO
    Via Investor Brand Network
    Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
    Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options 
    Via Benzinga
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
    Via Investor Brand Network
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Expands IP Portfolio with New Provisional Patent Application
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Health Care and Biotech Expert as New Chief Operating Officer
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
    Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
    Via Benzinga
    Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
    Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases. 
    Via Benzinga
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Results from Phase II Binge Eating Disorder Clinical Trial
    Via Investor Brand Network
    These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
    In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
    Via Benzinga
    PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board
    Via Investor Brand Network
    Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
    The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions. 
    Via Benzinga
    Could Magic Mushrooms Be A Solution For Overeating? New Clinical Trial Intends To Find Out
    Psilocybin, the active ingredient in “magic mushrooms,” could be part of the solution for people struggling with binge eating disorder, a condition characterized by recurring episodes of eating large... 
    Via Benzinga
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Doses First Patient in Clinical Trial for Psilocybin-Assisted Therapy Targeting BED
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Initiates Enrollment for Study to Evaluate TRP-8802 to Treat Binge Eating Disorder
    Via Investor Brand Network
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces New Board Appointment, Closing of First Tranche of Private Placement
    Via Investor Brand Network
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upsizing of Private Placement
    Via Investor Brand Network
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Q1 2022 Financial Numbers
    Via Investor Brand Network
    BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule
    Via Investor Brand Network
    FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics
    Tryp Therapeutics (CSE:TRYP) (OTCQB: 
    Via Benzinga
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Advancement of Binge-Eating Clinical Trial
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2021 Updates, Results
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’
    Via Investor Brand Network
    Exposures Product Safety
    FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process
    Via Investor Brand Network
    Topics Law Enforcement
    Exposures Legal Product Safety
    PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference
    Via Investor Brand Network
    PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’
    Via Investor Brand Network
    Exposures Product Safety
    Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays
    Via Investor Brand Network
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.